​

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRTX Stock Forecast

Vertex Pharmaceuticals (VRTX) stock forecast, based on 55 Wall Street analysts, predicts a 12-month average price target of $531.67, with a high of $606.00 and a low of $466.00. This represents a 14.33% increase from the last price of $465.02.

$350 $410 $470 $530 $590 $650 High: $606 Avg: $531.67 Low: $466 Last Closed Price: $465.02

VRTX Stock Rating

Vertex Pharmaceuticals stock's rating consensus is Buy, based on 55 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 46 Buy (83.64%), 9 Hold (16.36%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 55 0 9 46 Strong Sell Sell Hold Buy Strong Buy

VRTX Price Target Upside V Benchmarks

TypeNameUpside
StockVertex Pharmaceuticals14.33%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts61025
Avg Price Target$535.17$535.10$493.84
Last Closing Price$465.02$465.02$465.02
Upside/Downside15.09%15.07%6.20%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2641861130
Jan, 26217101131
Dec, 25118111132
Nov, 25217111132
Oct, 25217121-32
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 13, 2026RBC Capital$541.00$496.029.07%16.34%
Feb 13, 2026Bernstein$577.00$497.2116.05%24.08%
Feb 13, 2026Cantor Fitzgerald$590.00$495.1119.17%26.88%
Feb 13, 2026Paul MatteisStifel Nicolaus$466.00$465.020.21%0.21%
Feb 13, 2026Andrew FeinH.C. Wainwright$518.00$465.0211.39%11.39%
Jan 27, 2026Barclays$606.00$474.1727.80%30.32%
Jan 26, 2026UBS$545.00$474.0914.96%17.20%
Jan 23, 2026Cory KasimovEvercore ISI$530.00$469.1112.98%13.97%
Jan 22, 2026Brian AbrahamsRBC Capital$546.00$461.1418.40%17.41%
Jan 06, 2026Michael YeeUBS$535.00$468.3814.22%15.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 13, 2026ScotiabankOutperformOutperformhold
Feb 13, 2026BernsteinOutperformOutperformhold
Feb 13, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 13, 2026OppenheimerPerformOutperformupgrade
Feb 13, 2026H.C. WainwrightBuyBuyhold
Jan 27, 2026BarclaysEqual-WeightOverweightupgrade
Jan 26, 2026UBSBuyBuyhold
Jan 23, 2026Evercore ISIOutperformOutperformhold
Jan 22, 2026RBC CapitalSector PerformOutperformupgrade
Jan 12, 2026BernsteinOutperformupgrade

Financial Forecast

EPS Forecast

$-5 $2 $9 $16 $23 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.09$12.97$14.05$-2.08----
Avg Forecast$12.96$14.60$15.03$0.48$18.47$20.49$22.97$25.82
High Forecast$14.54$16.11$15.40$1.12$19.96$25.45$28.82$29.56
Low Forecast$12.26$13.86$14.65$0.06$16.67$17.06$19.12$24.25
Surprise %-29.86%-11.16%-6.52%-533.33%----

Revenue Forecast

$7B $9B $11B $13B $15B $17B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.57B$8.93B$9.87B$11.02B----
Avg Forecast$7.50B$8.93B$9.86B$10.89B$11.77B$12.86B$13.94B$15.25B
High Forecast$8.21B$9.64B$9.91B$10.97B$13.68B$12.87B$14.04B$16.94B
Low Forecast$7.19B$8.58B$9.79B$10.85B$11.22B$12.85B$13.85B$14.53B
Surprise %0.97%-0.03%0.06%1.17%----

Net Income Forecast

$-1B $800M $3B $4B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.34B$3.32B$3.62B$-535.60M----
Avg Forecast$2.08B$2.40B$3.62B$153.32M$4.77B$4.87B$5.30B$6.73B
High Forecast$2.50B$2.88B$4.34B$291.61M$5.20B$6.63B$7.51B$7.70B
Low Forecast$1.66B$1.92B$2.90B$15.03M$4.34B$4.44B$4.98B$6.32B
Surprise %12.58%38.24%--449.33%----

VRTX Forecast FAQ

Is Vertex Pharmaceuticals stock a buy?

Vertex Pharmaceuticals stock has a consensus rating of Buy, based on 55 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 46 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vertex Pharmaceuticals is a favorable investment for most analysts.

What is Vertex Pharmaceuticals's price target?

Vertex Pharmaceuticals's price target, set by 55 Wall Street analysts, averages $531.67 over the next 12 months. The price target range spans from $466 at the low end to $606 at the high end, suggesting a potential 14.33% change from the previous closing price of $465.02.

How does Vertex Pharmaceuticals stock forecast compare to its benchmarks?

Vertex Pharmaceuticals's stock forecast shows a 14.33% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vertex Pharmaceuticals over the past three months?

  • February 2026: 13.33% Strong Buy, 60.00% Buy, 20.00% Hold, 3.33% Sell, 3.33% Strong Sell.
  • January 2026: 6.45% Strong Buy, 54.84% Buy, 32.26% Hold, 3.23% Sell, 3.23% Strong Sell.
  • December 2025: 3.12% Strong Buy, 56.25% Buy, 34.38% Hold, 3.12% Sell, 3.12% Strong Sell.

What is Vertex Pharmaceuticals’s EPS forecast?

Vertex Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $18.47, marking a -987.98% decrease from the reported $-2.08 in 2024. Estimates for the following years are $20.49 in 2026, $22.97 in 2027, and $25.82 in 2028.

What is Vertex Pharmaceuticals’s revenue forecast?

Vertex Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $11.77B, reflecting a 6.80% increase from the reported $11.02B in 2024. The forecast for 2026 is $12.86B, followed by $13.94B for 2027, and $15.25B for 2028.

What is Vertex Pharmaceuticals’s net income forecast?

Vertex Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $4.77B, representing a -990.78% decrease from the reported $-536M in 2024. Projections indicate $4.87B in 2026, $5.3B in 2027, and $6.73B in 2028.